Get healthy returns from these three innovative healthcare stocks
Professional investor Michael Li of the American Century Advanced Medical Impact Fund looks at three healthcare stocks

Healthcare is an exciting sector. The incredibly rapid development of effective coronavirus vaccines is just one example of its tremendous potential for innovation and making a positive social impact. We also feel there is scope for healthy returns. Healthcare companies are innovating not just in therapeutics and medical devices, but also in terms of big data and analytics. As a result, we believe we are on the verge of a transformation in how care is delivered and diseases are treated.
Speeding up drug trials
Veeva Systems (NYSE: VEEV) is a cloud-software company whose technology helps plan drug trials safely and effectively. The process of developing a new drug takes over a decade and costs millions of dollars. This use of data analytics and information technology helps reduce approval times and costs, and raises the probability of success.
The company serves over 750 customers, including 20 of the largest pharmaceutical companies. Its technology typically accelerates regulatory submissions by 20%, which is crucial for patients likely to benefit from innovative treatments. Veeva’s platform also accelerates drug development by reducing the start-up time in clinical studies by 40%.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
A cocktail to combat Covid-19
Regeneron Pharmaceuticals (Nasdaq: REGN) is a biotechnology company engaged in the development of medicines for the treatment of serious diseases. It is pouring resources into research and development (R&D) and it maintains one of the world’s most comprehensive genetic databases, with a million people sequenced by the Regeneron Genetics Center. Regeneron is well known today for its Covid-19 antiviral drug cocktail, which has so far proved effective against the various strains of the disease, and is gaining market share from competing therapies. But Regeneron’s research effort goes far beyond Covid-19.
The company has developed and markets drugs addressing several serious medical conditions, including a type of inoperable skin cancer, wet age-related macular degeneration, asthma and eczema among others. Regeneron has approximately 30 potential treatments in clinical development.
Transforming diabetes care
DexCom (Nasdaq: DXCM) is an innovative medical-device company transforming the quality of life and standard of care for diabetics. The company produces a continuous glucose monitoring (CGM) system, which allows patients and care providers to evaluate and adjust care quickly and effectively in real time.
A sensor is placed under the patient’s skin and attached to a tiny transmitter that continuously relays data on blood-sugar levels. The data can be read on a dedicated receiver, displayed on an iPhone, or monitored remotely by a care provider. This technology is transformative: traditional glucose monitoring depends on intermittent, inconvenient and painful finger pricks and self-monitoring.
Not only is DexCom attractive for its positive impact on the lives of diabetics, but the company is also gaining market share, broadening the range of potential applications for its products and expanding geographically.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Council tax bills in worst hit areas set to rise by £500 in the next four years
Branded the ‘ultimate stealth tax’, the council tax burden is increasing across the country, with some areas potentially having to find hundreds of pounds more a year to pay the bill
-
Crypto ETNs are approved for UK retail investors
The FCA has approved the sale of crypto ETNs to retail investors from October. What is a crypto ETN, and what does this mean for investors?
-
Global equities that should prove resilient to the stock market’s storms
Opinion Alex Illingworth of Goshawk Asset Management highlights three diverse opportunities in global equities despite a turbulent landscape
-
FRP Advisory Group – a bargain in a booming market
FRP Advisory Group's past and future growth isn’t reflected in the company’s valuation
-
European funds: investors have 'a luxury of choice'
A series of mergers is bringing consolidation among European funds, but investors should benefit, says Max King
-
US stocks are more expensive than ever after Trump's tariffs
We don’t need to second-guess the effect of Trump's tariffs to think that the rest of the world offers better value
-
How to use SAYE and SIP schemes to multiply your money
Employers’ savings or share-incentive plans like SAYE and SIP schemes can help top up your pension
-
Sizzling sales at Sysco – should you invest in this US food supplier?
The American food distribution group Sysco is expanding rapidly worldwide and is still reasonably valued
-
Where investors can find value now
Opinion Active fund managers and blue chips on both sides of the Atlantic look appealing, says ByteTree’s Charlie Morris
-
How to balance growth and income when investing
Dividend-paying stocks have beaten the market. That doesn’t mean that income funds will do best